Research programme: skin disorder topical therapeutics - Foamix

Drug Profile

Research programme: skin disorder topical therapeutics - Foamix

Alternative Names: Benzoyl peroxide foam - Foamix; Betamethasone dipropionate foam - Foamix; Calcipotriene foam - Foamix; Calcipotriol foam - Foamix; Ciclopirox foam - Foamix; Ciclopiroxolamine foam - Foamix; Clobetasol propionate foam - Foamix; Lactic acid/urea foam - Foamix; Salicylic acid foam - Foamix; Triamcinolone acetonide foam - Foamix; U-LAC foam; UFoam; Urea foam - Foamix; Urea/lactic acid foam - Foamix

Latest Information Update: 08 Oct 2014

Price : $50

At a glance

  • Originator Foamix
  • Developer Foamix; Therapeutics Incorporated
  • Class Benzoic acids; Corticosteroids; Cyclohexanes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Hydroxy acids; Indenes; Lactates; Oxidants; Pregnadienes; Pyridones; Salicylates; Small molecules; Urea compounds; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors; Mitosis inhibitors; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne; Atopic dermatitis; Dermatomycoses; Dry skin; Psoriasis; Seborrhoeic dermatitis
  • No development reported Hyperhidrosis

Most Recent Events

  • 08 Oct 2014 FDX 104 (doxocycline foam) enters clinical development for exanthema (chemotherapy-induced) in Israel (Topical)
  • 02 Jul 2014 No development reported for Psoriasis, Atopic dermatitis and Seborrhoeic dermatitis in USA (Topical)
  • 02 Jul 2014 No development reported for Hyperhidrosis in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top